Press releases

August 25, 2026

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more

August 19, 2026

Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)

Read more

August 04, 2026

Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update

Read more

July 28, 2026

Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update

Read more

July 24, 2026

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more

July 08, 2026

Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact

Read more

June 19, 2026

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more

June 03, 2026

Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference

Read more

May 22, 2026

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more

May 06, 2026

Ultragenyx to Participate at Bank of America’s 2026 Healthcare Conference

Read more